<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T00:58:16Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:20.500.14342/747" metadataPrefix="mets">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:20.500.14342/747</identifier><datestamp>2025-05-15T19:18:05Z</datestamp><setSpec>com_2072_482405</setSpec><setSpec>com_2072_183628</setSpec><setSpec>col_2072_482409</setSpec></header><metadata><mets xmlns="http://www.loc.gov/METS/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" ID="&#xa;&#x9;&#x9;&#x9;&#x9;DSpace_ITEM_20.500.14342-747" TYPE="DSpace ITEM" PROFILE="DSpace METS SIP Profile 1.0" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd" OBJID="&#xa;&#x9;&#x9;&#x9;&#x9;hdl:20.500.14342/747">
   <metsHdr CREATEDATE="2026-04-13T02:58:16Z">
      <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
         <name>RECERCAT</name>
      </agent>
   </metsHdr>
   <dmdSec ID="DMD_20.500.14342_747">
      <mdWrap MDTYPE="MODS">
         <xmlData xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
            <mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fernández Jané, Carles</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Vilaro, Jordi</mods:namePart>
               </mods:name>
               <mods:extension>
                  <mods:dateAccessioned encoding="iso8601">2025-05-15T19:18:05Z</mods:dateAccessioned>
               </mods:extension>
               <mods:extension>
                  <mods:dateAvailable encoding="iso8601">2025-05-15T19:18:05Z</mods:dateAvailable>
               </mods:extension>
               <mods:originInfo>
                  <mods:dateIssued encoding="iso8601">2019-12</mods:dateIssued>
               </mods:originInfo>
               <mods:identifier type="uri">http://hdl.handle.net/20.500.14342/747</mods:identifier>
               <mods:identifier type="doi">https://dx.doi.org/10.1186/s13063-019-3757-x</mods:identifier>
               <mods:abstract>Background&#xd;
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a major cause of hospital admissions and dyspnoea is its main symptom. Some studies have concluded that a new modality of acupuncture, called acupoint transcutaneous electrical nerve stimulation (acuTENS), could reduce dyspnoea in patients with COPD by increasing β-endorphin levels. However, those trials have been conducted mainly on patients in stable condition. This study aims to determine whether the administration of acuTENS can reduce dyspnoea in patients hospitalized for AECOPD.&#xd;
&#xd;
Methods&#xd;
A multicentre randomized control trial with blinding of participants and assessors will be conducted. A sample of 60 patients will be randomly assigned to receive 45 min of either real acuTENS or sham acuTENS treatment once a day for five consecutive days. The trial will be conducted at the “Hospital del Mar” in Barcelona (Spain) and the “Hospital Sant Joan de Déu de Manresa” in Manresa (Spain). The Borg scale at baseline and days 1 to 5 will be the primary outcome. Secondary outcomes will be the duration of the hospitalization, quantity of drugs administrated, expiratory peak flow adverse effects and mortality and readmissions at 3 months.&#xd;
&#xd;
Discussion&#xd;
AcuTENS is a non-pharmacological, non-invasive and inexpensive intervention. This trial will help to elucidate the potential role of acuTENS in the treatment of AECOPD.</mods:abstract>
               <mods:language>
                  <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
               </mods:language>
               <mods:accessCondition type="useAndReproduction">Attribution 4.0 International © L'autor/a</mods:accessCondition>
               <mods:subject>
                  <mods:topic>Pulmons -- Malalties obstructives</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Dispnea</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Acupuntura</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Neuroestimulació</mods:topic>
               </mods:subject>
               <mods:titleInfo>
                  <mods:title>Acupoint transcutaneous electrical nerve stimulation in hospitalized COPD patients with severe dyspnoea: study protocol for a randomized controlled trial</mods:title>
               </mods:titleInfo>
               <mods:genre>info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion</mods:genre>
            </mods:mods>
         </xmlData>
      </mdWrap>
   </dmdSec>
   <structMap LABEL="DSpace Object" TYPE="LOGICAL">
      <div TYPE="DSpace Object Contents" ADMID="DMD_20.500.14342_747"/>
   </structMap>
</mets></metadata></record></GetRecord></OAI-PMH>